OasisLMS

1. To register, press the "Login" or "Get Started" button.
2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”

In this video, the authors and SCAI experts discuss findings from the BENELUX‑IVL registry evaluating the incidence, management, and outcomes of complications following coronary intravascular lithotripsy in an all‑comers PCI population.

They highlight a low overall complication rate, procedural success, and important differences in clinical outcomes between patients with and without complications. They also discuss predictors of complications and practical implications for optimizing IVL use in real‑world practice.

Join Drs. Goldsweig, Montero-Cabezas, van Oort, Claessen, and Davies in their discussion of this original research article.

Read the article here: https://www.jscai.org/article/S2772-9303(25)01148-2/fulltext

• Recognize the overall safety profile of coronary intravascular lithotripsy (IVL) when used in contemporary, real‑world clinical practice.
• Understand the types of complications that may occur during procedures involving IVL and how they are typically identified and managed.
• Discuss the potential impact of procedural complications on short‑ and longer‑term clinical outcomes.
• Apply general principles from recent evidence to support safe and effective use of IVL in patients with calcified coronary lesions.

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. This activity was developed by the Journal Editor-in-Chief and reviewed and approved by the Editorial Board. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.